Trovagene Investor Relations http://trovagene.investorroom.com/ Trovagene Investor Relations Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML http://trovagene.investorroom.com/2018-02-13-Trovagene-Announces-Activation-of-Two-Additional-Clinical-Trial-Sites-to-Conduct-its-Phase-1b-2-Study-of-PCM-075-in-Patients-with-AML Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in Acute Myeloid Leukemia (AML) Tue, 13 Feb 2018 05:00:00 -0800 http://trovagene.investorroom.com/2018-02-13-Trovagene-Announces-Activation-of-Two-Additional-Clinical-Trial-Sites-to-Conduct-its-Phase-1b-2-Study-of-PCM-075-in-Patients-with-AML Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium http://trovagene.investorroom.com/2018-02-09-Trovagene-Presents-Data-Showing-Synergy-of-PCM-075-in-Combination-with-Zytiga-R-in-Castration-Resistant-Prostate-Cancer-Model-at-2018-Genitourinary-Cancers-Symposium Targeted treatment with highly-selective Polo-like Kinase 1 inhibitor PCM-075 in combination with Zytiga® (abiraterone acetate) may represent a new treatment option in CRPC Fri, 09 Feb 2018 12:15:00 -0800 http://trovagene.investorroom.com/2018-02-09-Trovagene-Presents-Data-Showing-Synergy-of-PCM-075-in-Combination-with-Zytiga-R-in-Castration-Resistant-Prostate-Cancer-Model-at-2018-Genitourinary-Cancers-Symposium Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML) http://trovagene.investorroom.com/2018-02-06-Trovagene-Announces-Completion-of-Cycle-One-Dosing-in-First-Patient-Enrolled-in-its-Phase-1b-2-Clinical-Trial-of-PCM-075-in-Acute-Myeloid-Leukemia-AML Tue, 06 Feb 2018 05:00:00 -0800 http://trovagene.investorroom.com/2018-02-06-Trovagene-Announces-Completion-of-Cycle-One-Dosing-in-First-Patient-Enrolled-in-its-Phase-1b-2-Clinical-Trial-of-PCM-075-in-Acute-Myeloid-Leukemia-AML Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) http://trovagene.investorroom.com/2018-01-24-Trovagene-Announces-Initiation-of-UNITE-Phase-2-Clinical-Trial-of-PCM-075-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-mCRPC PCM-075, Trovagene's highly-selective Polo-like Kinase 1 (PLK1) inhibitor may extend patient response to therapy when used in combination with Zytiga® (abiraterone) in mCRPC Wed, 24 Jan 2018 05:00:00 -0800 http://trovagene.investorroom.com/2018-01-24-Trovagene-Announces-Initiation-of-UNITE-Phase-2-Clinical-Trial-of-PCM-075-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-mCRPC Trovagene to Present at the Biotech Showcase™ Annual Conference http://trovagene.investorroom.com/2018-01-03-Trovagene-to-Present-at-the-Biotech-Showcase-TM-Annual-Conference Wed, 03 Jan 2018 05:00:00 -0800 http://trovagene.investorroom.com/2018-01-03-Trovagene-to-Present-at-the-Biotech-Showcase-TM-Annual-Conference